Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Br J Dermatol. 2015 Feb 5;172(3):760–768. doi: 10.1111/bjd.13350

Figure 1.

Figure 1

Change in the number of days per week with new blisters in subjects treated with infliximab compared to placebo. Subjects in the per-protocol group treated with infliximab exhibited a decrease in the number of new blisters per week during the study whereas subjects treated with placebo showed an increase in the number of new blisters per week. (p= 0.037)